A Practical Update on the Use of Bortezomib in the Management of Multiple Myeloma-Reference-Cited by-同舟云学术

A Practical Update on the Use of Bortezomib in the Management of Multiple Myeloma

Published:2006-01-01 Issue:1 Volume:11 Page:51-61
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

San Miguel Jesús¹,Bladé Joan²,Boccadoro Mario³,Cavenagh Jamie⁴,Glasmacher Axel⁵,Jagannath Sundar⁶,Lonial Sagar⁷,Orlowski Robert Z.⁸,Sonneveld Pieter⁹,Ludwig Heinz¹⁰

Affiliation:

1. a Hospital Clinico Universitario de Salamanca, Salamanca, Spain

2. b Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

3. c University of Turin, Turin, Italy

4. d St. Bartholomew's Hospital, London, United Kingdom

5. e University of Bonn, Bonn, Germany

6. f St Vincent's Comprehensive Cancer Center, New York, New York, USA

7. g Winship Cancer Institute, Atlanta, Georgia, USA

8. h Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA

9. i Virchow-University Hospital, Berlin, Germany

10. j Erasmus Medical Center, Rotterdam, The Netherlands

Abstract

Learning Objectives After completing this course, the reader will be able to: Discuss clinical trial data for treatment with bortezomib monotherapy and bortezomib-based combination therapy in patients with multiple myeloma who have received at least one prior therapy.Discuss the management of the most common adverse events associated with bortezomib, including peripheral neuropathy and thrombocytopenia.Describe prognostic factors in patients with multiple myeloma who have received at least one prior therapy. Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.com

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.11-1-51

Reference32 articles.

1. Thalidomide and new drugs for the treatment of multiple myeloma;San Miguel;Hematol J,2003

2. New drugs for treatment of multiple myeloma;Bruno;Lancet Oncol,2004

3. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341;Hideshima;Blood,2003

4. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications;Mitsiades;Blood,2003

5. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies;Orlowski;J Clin Oncol,2002

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Determination of drug-related problems in the hematology service: a prospective interventional study;BMC Cancer;2024-05-02

2. SKping cell cycle regulation: role of ubiquitin ligase SKP2 in hematological malignancies;Frontiers in Oncology;2024-03-15

3. A case report on bortezomib-induced paralytic ileus;National Journal of Pharmacology and Therapeutics;2024-01

4. Bortezomib Is Toxic but Induces Neurogenesis and Inhibits TUBB3 Degradation in Rat Neural Stem Cells;Biomolecules & Therapeutics;2023-12-11

5. Inhibitors of the Mechanistic Target of Rapamycin Can Ameliorate Bortezomib-Induced Peripheral Neuropathy;Biological and Pharmaceutical Bulletin;2023-08-01